CombiGene AB (publ)
SSTO:COMBIShare Statistics
As of December 31, 2024, CombiGene AB (publ) has 19.80M shares outstanding.
| Shares Outstanding | 19.80M |
Valuation Ratios
These figures are as of December 31, 2024. The price-to-sales ratio is 144.56, and the price-to-book ratio stands at -1.07.
| PS Ratio | 144.56 |
| PB Ratio | -1.07 |
| P/TBV Ratio | 0.66 |
| P/FCF Ratio | -1.57 |
| P/OCF Ratio | -1.57 |
Financial Position
As of December 31, 2024, CombiGene AB (publ) maintains a current ratio of 17.47, meaning it holds 17.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 17.47 |
| Quick Ratio | 17.15 |
Financial Efficiency
These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -45.68, reflecting losses generated across the asset base.
| Return on Assets (ROA) | -45.68 |
Margins
Over the twelve months ended December 31, 2024, CombiGene AB (publ) posted a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -14,484.05 and net profit margin of -13,765.95 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -14,484.05 |
| Pretax Margin | -13,765.95 |
| Profit Margin | -13,765.95 |
| EBITDA Margin | -14,484.05 |
Dividends & Yields
These figures cover the twelve months ended December 31, 2024. Free cash flow yield is negative at -63.55: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.
| FCF Yield | -63.55 |
Stock Splits
CombiGene AB (publ)'s most recent stock split took place on June 7, 2021 with a 20:1 split ratio.
| Last Split Date | 6/7/2021 |
| Split Ratio | 20:1 |
Scores
As of December 31, 2024, CombiGene AB (publ) has an Altman Z-Score of 4.82, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.82 |